Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate

Laboratory Investigation

Volumn 82, Issue 11, 2002, Pages 1573-1582

  Porkka, Kati P ^a   Helenius, Merja A ^a   Visakorpi, Tapio ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANDROGEN; COMPLEMENTARY DNA; DNA; GREEN FLUORESCENT PROTEIN; MEMBRANE PROTEIN; PROSTATE ANTIGEN; RNA;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA SEQUENCE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDIZATION; IN SITU HYBRIDIZATION; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY;

EID: 0036849009     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000038554.26102.C6     Document Type: Article

References (22)

1. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, and Jenkins RB (1994). Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998-4002.
2. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, and Isaacs WB (1999). DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975-5979.
3. Chang GT, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ, and Brinkmann AO (1997). Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res 57:4075-4081.
4. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, and Siebert PD (1996). Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 93:6025-6030.
5. Hubank M and Schatz DG (1994). Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 22:5640-5648.
6. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, and Afar DE (1999). STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96:14523-14528.
7. Korkmaz KS, Elbi CC, Korkmaz CG, Loda M, Hager GL, and Saatcioglu F (2002). Molecular cloning and characterization of STAMP1, a highly prostate specific six-trans-membrane protein that is overexpressed in prostate cancer. J Biol Chem 277:36689-36696.
8. Li LC, Chui R, Nakajima K, Oh BR, Au HC, and Dahiya R (2000). Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression. Cancer Res 60:702-706.
9. Liang P and Pardee AB (1992). Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967-971.
10. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, and Visakorpi T (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555.
11. Moldes M, Lasnier F, Gauthereau X, Klein C, Pairault J, Feve B, and Chambaut-Guerin AM (2001). Tumor necrosis factor-alpha-induced adipose-related protein (tiarp), a cell-surface protein that is highly induced by tumor necrosis factor-alpha and adipose conversion. J Biol Chem 276:33938-33946.
12. Nupponen NN, Porkka K, Kakkola L, Tanner M, Persson K, Borg Å, Isola J, and Visakorpi T (1999). Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol 154:1777-1783.
13. Porkka KP and Visakorpi T (2001). Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array. J Pathol 193:73-79.
14. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, and Witte ON (1998). Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95:1735-1740.
15. Rinaldy AR, Menon RP, Lerner JL, and Steiner MS (2000). Role of pHyde novel gene product as an intrinsic factor for apoptotic pathway in prostate cancer. Gan To Kagaku Ryoho 27(Suppl 2):215-222.
16. Rinaldy AR and Steiner MS (1999). Application of an improved cDNA competition technique to identify prostate cancer-associated gene. DNA Cell Biol 18:829-836.
17. Sambrook J, Fritsch EF, and Maniatis T (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
18. Schena M, Shalon D, Davis RW, and Brown PO (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470.
19. Steiner MS, Zhang X, Wang Y, and Lu Y (2000). Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde. Cancer Res 60:4419-4425.
20. Velculescu VE, Zhang L, Vogelstain B, and Kinzler KW (1995). Serial analysis of gene expression. Science 270: 484-487.
21. Visakorpi T, Kallioniemi A, Syvänen A-C, Hyytinen E, Karhu R, Tammela T, Isola J, and Kallioniemi O-P (1995). Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347.
22. Yang D, Holt GE, Velders MP, Kwon ED, and Kast WM (2001). Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: Prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61:5857-5860.